The invention relates to bacteriophage means, namely intracorporal bacteriophage means, nasopharyngeal and pulmonary bacteriophage means, cutaneous bacteriophage means, and bacteriophage suture means, and in addition a two-syringe bacteriophage means, a nasopharyngeal and pulmonary bacteriophage means device, and a bacteriophage sensitive testing application.

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

The invention relates a pharmaceutical composition comprising from 0.001 to 2% (w/v) of propane-1,2-diol as the only anti-inflammatory agent and at least one bioadhesive polymer. The pharmaceutical composition can be used in amelioration, prevention or treatment of an inflammatory condition in a mucous membrane or skin of a subject, and/or in treatment of pain associated with such an 5 inflammatory condition.

The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.

Described herein are electrospun core-shell fibers that include (i) a central core that is electrically conductive having an exterior surface, wherein the core comprises a first polymer and an electroconductive material; (ii) a shell adjacent to the exterior surface of the core, the shell comprising a second polymer; and (iii) one or more bioactive agents in the shell. In one aspect, the fibers are electrospun fibers. Additionally, described herein are methods for making and using the core-shell fibers.

Solid films and articles having a surface with discrete regions patterned with a deposited low molecular weight organic compound, such as pharmaceutical actives and new chemical entities, are provided. The organic compound may be present at ≥ about 99 mass % in the one or more discrete regions and may be crystalline or amorphous. The deposited organic compound may be deposited as a film having high surface area. The deposited organic compound exhibits enhanced solubility and bioavailability, by way of non-limiting example. Methods of organic vapor jet printing deposition method of such a low molecular weight organic compound in an inert gas stream are also provided.

Active substances for which controlled release is desired, are released by a process in which a shaped body (S) containing a composition (C) comprises a silicone-containing polymer (P) containing at least one Si—C bonded amino acid group and active substance (A) is contacted with water, resulting in the release of active substance (A) from the composition (C).

In an example of a method for making a pulsatile delivery device, one type of charges are generated on a polymeric layer, and charges opposite the one type of charges are generated on a delivery layer including a film forming material and a predetermined substance dispersed throughout the film forming material. The charged polymeric and delivery layers are placed into contact to form a bi-layer structure. A stack with at least two bi-layer structures is formed so that the polymeric layers and the delivery layers are alternating throughout the stack. The stack is sealed so that one of the polymeric layers remains exposed.

Described herein are compositions in the form of wet wipes comprising active agents to treat hemorrhoids. The compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent. Additionally described herein are methods for treating hemorrhoids comprising applying to an affected area of a person in need thereof a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.

A wipe has a substrate, a treatment solution impregnated into the substrate, the treatment solution including an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution is essentially free of alcohol. A treatment solution, has an antifungal agent, an antifungal agent solvent, and a carrier fluid, wherein the treatment solution has an alcohol content of 6 wt % or below of the total solution.